Completed PHASE2 INTERVENTIONAL 3-arm NCT00370682

A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand

Phase II, Randomized, Double-blind, Single Center, Controlled Study of Two Doses of Different Formulations of the WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to a Placebo Control, Administered on a 0-6 Month Schedule, to Healthy Adults

Sponsor: GlaxoSmithKline

Conditions Dengue

Interventions Placebo Comparator T-DEN F-19 T-DEN F17

Updated 8 times since 2017 Last updated: May 23, 2017 Started: Apr 30, 2007 Primary completion: Feb 29, 2008 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00370682, this PHASE2 trial focuses on Dengue and remains completed. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Aug 2019 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jul 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Jul 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
U.S. Army Medical Research and Development Command

Data source: U.S. Army Medical Research and Development Command

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bangkok, Thailand